27 papers · ranked by Valyu relevance
Krupa Naran, Trishana Nundalall, Shivan Chetty, Stefan Barth
The advances in cancer biology and pathogenesis during the past two decades, have resulted in immunotherapeutic strategies that have revolutionized the treatment of malignancies, from relatively non-selective toxic agents to specific, mechanism-based therapies. Despite extensive global efforts, infectious diseases…
Ritika Sharma
Immunotherapy, a therapeutic strategy aimed at modulating the host immune system, has undergone rapid evolution over recent decades, particularly in oncology. Advanced methodologies, including immune checkpoint inhibition, cytokine therapy, chimeric antigen receptor T-cell therapy (CAR-T), and tumor-infiltrating…
Shiu-Jau Chen, Shao-Cheng Wang, Yuan-Chuan Chen, Federico Cappuzzo
Immunotherapy is a novel anti-cancer method which employs a different mechanism to conventional treatment. It has become a significant strategy because it provides a better or an alternative option for cancer patients. Recently, immunotherapy has been increasingly approved for the treatment of cancer; however, it has…
J. Hammerbacher, A. Snyder
The rapid development of immunomodulatory cancer therapies has led to a concurrent increase in the application of informatics techniques to the analysis of tumors, the tumor microenvironment, and measures of systemic immunity. In this review, the use of tumors to gather genetic and expression data will first be…
Xiaoyuan Chen, Mingnan Chen
Immunity is the most critical and well-regulated protection to the body. Immunity is implicated in a wide range of diseases and serves as the foundation for immunotherapy. Immunotheranostics is the idea of improving immunotherapy through the organic integration of therapeutic, diagnostic, and screening technologies.…
David B. Page, Ariel Bulua Bourla, Anthony Daniyan, Jarushka Naidoo + 9 more
'Eric Smith' 'Melody Smith' 'Claire Friedman' 'Danny N. Khalil' 'Samuel Funt' 'Alexander N. Shoushtari' 'Willem W. Overwijk' 'Padmanee Sharma' 'Margaret K. Callahan'] The pioneers of tumor immunology and cancer immunotherapy, including the late William B. Coley and Lloyd J. Old, have championed the potential for…
Qian Li, Xu Lei, Jing Zhu, Yanping Zhong + 3 more
'Jincheng Wang' 'Huabing Tan'] Cancer immunotherapy has drawn much attention because it can restart the recognition and killing function of the immune system to normalize the antitumor immune response. However, the role of radiotherapy and chemotherapy in cancer treatment cannot be ignored. Due to cancer heterogeneity…
Kavita Iyer, Julian Ivanov, Rumiana Tenchov, Krittika Ralhan + 4 more
Rapid and sustained growth in the field of immuno-oncology has resulted in expansion of available scientific literature. Gaining valuable insights and establishing deep and often hidden meaningful connections in such a large body of work is the need of the hour. In this report we summarize our findings from a novel…
Erfan Rezazadeh‐Gavgani, Reza Majidazar, Parisa Lotfinejad, Tohid Kazemi + 1 more
3## Immunotherapy Immunotherapy alters the immune system to treat cancer(s). It is a type of biological therapies used for treating cancers and includes different methods such as ICIs, vaccines, and cytokines . In this article, we have focused on ICIs and their applicability in various cancers, providing their…
Authors not listed
Immuno-oncology, a rapidly evolving field at the forefront of cancer research, leverages the body’s immune system to fight cancer. In this follow up report, we extend our natural language processing (NLP)-based analysis to pinpoint the context of emergence of the previously identified emerging concepts. To achieve this…
Authors not listed
Blinatumomab is an FDA-approved bispecific T Cell engager(BiTE) that binds CD3 on T cells and CD19 on B cells, redirecting cytotoxic T cell activity to malignant B cells. Blinatumomab has achieved clinical success in treating B-cell acute lymphoblastic leukemia(B-ALL), however, the structural and functional…
Kamran Kaveh, Feng Fu
Immune checkpoint therapy is one of the most promising immunotherapeutic methods that are likely able to give rise to durable treatment response for various cancer types. Despite much progress in the past decade, there are still critical open questions with particular regards to quantifying and predicting the efficacy…
Carmen Criscitiello, Michele Santangelo, Fotios Loupakis
The immune system is naturally able to detect and destroy abnormal cells thus preventing the development of many cancers. Nevertheless, sometimes cancer cells may avoid detection and destruction by the immune system. Cancer cells may decrease the expression of tumor antigens on their surface, making it harder for the…
Anna Konstorum, Anthony T. Vella, Adam C. Adler, Reinhard Laubenbacher
'Reinhard Laubenbacher'] The goal of cancer immunotherapy is to boost a patient's immune response to a tumor. Yet, the design of an effective immunotherapy is complicated by various factors, including a potentially immunosuppressive tumor microenvironment, immune-modulating effects of conventional treatments, and…
Paula Kroon, Elselien Frijlink, Victoria Iglesias-Guimarais, Andriy Volkov + 5 more
To increase cancer immunotherapy success, PD-1 blockade must be combined with rationally selected treatments. Here, we examined in a poorly immunogenic mouse breast cancer model the potential of antibody-based immunomodulation and conventional anti-cancer treatments to collaborate with anti-PD-1 treatment. One…
A Hoefges, SJ McIlwain, AK Erbe, N Mathers + 15 more
Antibodies can play an important role in innate and adaptive immune responses against cancer, and in preventing infectious disease. Flow cytometry analysis of sera of immune mice that were previously cured of their melanoma through a combined immunotherapy regimen with long-term memory showed strong antibody-binding…
Collin Y. Zheng, Peter Kim
We introduce a set of ordinary differential equations (ODE) that qualitatively reproduces delayed responses observed in immune checkpoint blockade therapy (e.g. anti-CTLA-4 Ipilimumab). This type of immunotherapy has been at the forefront of novel and promising cancer treatments over the past decade and was recognised…
Guangchuan Wang, Feifei Zhang, Ryan D. Chow, Emily He + 3 more
The hostile tumor microenvironment (TME) is major challenge for cancer immunotherapies. Here, we design and perform TME-targeted in vivo CRISPR activation (CRISPRa) screens to uncover factors that promote anti-tumor immunity, culminating in rationally designed immune gene therapy combinations. Through adeno-associated…
Daniel Y. Yuan, Michelle L. McKeague, Vineet K. Raghu, Robert E. Schoen + 2 more
A single arm trial (NCT007773097) and a double-blind, placebo controlled randomized trial (NCT02134925) were conducted in individuals with a history of advanced colonic adenoma to test the safety and immunogenicity of the MUC1 tumor antigen vaccine and its potential to prevent new adenomas. These were the first two…
Naman Kumar Mehta, Anjali Lathwal, Rajesh Kumar, Dilraj Kaur + 1 more
Interleukin-2 (IL-2) based immunotherapy has been approved for treating certain types of cancer, as IL-2 plays a crucial role in regulating the immune system. In this study, we developed a method for predicting IL-2-inducing peptides. Our method was trained, tested, and validated on a main dataset containing 6,574…
Weizhi Wang, Limin Zhang
Blocking programmed cell death ligand 1 (PD-L1) in tumor cells is an effective therapy strategy to achieve immune system activation for tumor therapy, however only a few patients can benefit from it. Development of synergistic therapy with checkpoint PD-L1 blockade immunotherapy is beneficial to enhance antitumor…
Isabel González‐Crespo, Antonio Gómez‐Caamaño, Óscar López Pouso, John D. Fenwick + 1 more
'John D. Fenwick' 'Juan Pardo‐Montero'] There is evidence of synergy between radiotherapy and immunotherapy. Radiotherapy can increase liberation of tumor antigens, causing activation of antitumor T-cells. This effect can be boosted with immunotherapy. Radioimmunotherapy has potential to increase tumor control rates.…
Shalla Hanson, David Robert Grimes, Jake P. Taylor-King, Benedikt Bauer + 10 more
Advances in genetic engineering have made it possible to reprogram individual immune cells to express receptors that recognise markers on tumour cell surfaces. The process of re-engineering T cell lymphocytes to express Chimeric Antigen Receptors (CARs), and then re-infusing the CAR-modified T cells into patients to…
Authors not listed
Melanoma is a type of skin cancer originating in the melanocytes and is recognized as one of the most severe and challenging forms of skin cancer to treat. Tyrosinase-related protein 1 (TYRP1) is a crucial protein involved in melanin production and is notably overexpressed in melanoma cells. Recently, TYRP1 has been…
Tibor Bakács, Katalin Kristóf, J.N. Mehrishi, Tamás Szabados + 3 more
'Csaba Kerepesi' 'Enikoe Regoes' 'Gábor Tusnády'] 1Department of Probability, Alfred Renyi Institute of Mathematics, The Hungarian Academy of Sciences, 1053 Budapest, Reáltanoda str. 13-15. Hungary; 2Department of Anesthesiology, Emergency and Intensive Care Medicine, University of Göttingen, Robert-Koch-Str. 40…
Authors not listed
Hodgkin’s lymphoma is a malignancy (cancer) that affects the immune system, primarily lymphocytes (white blood cells). CD30 is a protein receptor expressed on the surface of Hodgkin's cancer cells and is a crucial target for diagnosis and treatment. As of now, current CD30-targeted therapies come with extensive side…
Li, Chenghang, Lei, Jinzhi
Mathematical oncology is a rapidly evolving interdisciplinary field that uses mathematical models to enhance our understanding of cancer dynamics, including tumor growth, metastasis, and treatment response. Tumorimmune interactions play a crucial role in cancer biology, influencing tumor progression and the…